Business Context and Reporting Period
Tenon Medical, Inc. (TNON) filed a Form 8-K on January 4, 2024, reporting a corporate governance event. The company is incorporated in Delaware and its common stock and warrants trade on The Nasdaq Stock Market LLC.
Key Financial Metrics
This filing is a current report regarding a listing rule compliance issue and does not contain financial statements. Revenue, profit, cash flow, margins, debt, and liquidity metrics are not provided in this document.
Material Changes
The material change reported is the resignation of Frank Fischer from the Board of Directors, Audit Committee, and Compensation Committee, effective November 30, 2023. This resignation resulted in the company falling out of compliance with Nasdaq Listing Rule 5605 regarding the required number of independent directors on the Board and its committees.
Outlook, Risks, and Contingencies
- Compliance Status: The company received a notice from Nasdaq indicating non-compliance with Listing Rule 5605. The Board currently has six directors, only three of whom are independent. The Audit Committee has only two independent directors, and the Compensation Committee has only one.
- Cure Period: The company has a cure period until the earlier of its next annual shareholders' meeting or November 30, 2024. If the next annual meeting is held before May 28, 2024, compliance must be evidenced by May 28, 2024.
- Management Plan: Management intends to elect one or more independent directors to the Board, Audit Committee, and Compensation Committee during the cure period.
- Trading Impact: The notice has no immediate effect on the listing or trading of the company's common stock on The Nasdaq Capital Market.
Investor Verification Checklist
- Verify the timeline for the company's next annual shareholders' meeting to determine the exact deadline for restoring compliance.
- Monitor future filings (such as 8-Ks or proxy statements) for the appointment of new independent directors.
- Confirm that the resignation of Frank Fischer was not accompanied by undisclosed financial or operational issues.
- Review the company's most recent 10-K or 10-Q for actual financial performance data, as this filing contains none.